Sees Bone Growth Therapies growth of 15%, marking four consecutive quarters with double-digit net sales increases, and representing the strongest quarter of Bone Growth Therapies sales in the history of Orthofix U.S. Spinal Implants, Biologics, and Enabling Technologies growth of 4% on a pro forma basis over Q4 2022 Global Orthopedics net sales increase of 7% on a reported basis over Q4 2022.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on OFIX:
- Orthofix announces Massimo Calafiore assumes CEO role, names Julie Andrews CFO
- Orthofix publishes new data from PEMF stimulation study
- Sealed Air, SolarEdge, Orthofix to join S&P 600 at open on 12/18
- Orthofix enters cooperation pact with Engine Capital, names three board members
- Orthofix gets published in Spine Journal of 5 yr data on M6-C cervical disc
